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Background: A broad range of gemcitabine dosages have been used in dogs.
Hypothesis/Objectives: To determine maximally tolerated dose (MTD), dose-limiting toxicity (DLT), and preliminary
antitumor activity of intravenous administration of gemcitabine in dogs with advanced solid tumors.
Animals: Twenty-two client-owned dogs.
Methods: Dogs with advanced cancer were prospectively enrolled in an open-label Phase 1 study of gemcitabine. Gemcita-
bine was administered as a 30-minute intravenous bolus starting at 800 mg/m2, using escalation of 50 mg/m2 increments with
3 dogs per dose level. MTD was established based on the number of dogs experiencing DLT assessed after 1 cycle. Treatment
continued until disease progression or unacceptable toxicosis. Additional dogs were enrolled at MTD to better characterize
tolerability, and to assess the extent and duration of gemcitabine excretion.
Results: Twenty-two dogs were treated at 4 dose levels, ranging from 800 to 950 mg/m2. Neutropenia was identiﬁed as
DLT. MTD was 900 mg/m2. DLT consisting of grade 4 febrile neutropenia was observed at 950 mg/m2 in 2 dogs. There were
no nonhematologic DLTs. Twenty dogs received multiple doses, and none had evidence of severe toxicosis from any of their
subsequent treatments. At 900 mg/m2, 2 complete and 5 partial responses were observed in dogs with measurable tumors.
The amount of gemcitabine excreted in urine decreased over time, and was undetectable after the ﬁrst 24 hours.
Conclusions and Clinical Importance: The recommended dose of gemcitabine for future Phase 2 studies is weekly 900 mg/m2.
In chemotherapy-na€ıve dogs with advanced solid tumor this dose level merits further evaluation.
Key words: Canine; Dose-limiting toxicity; Gemzar; Maximally tolerated dose.
Gemcitabine is an antimetabolite analog to cytidinewith unique metabolic and mechanistic proper-
ties.1,2 Preliminary studies conducted in dogs have
shown a mild, schedule-dependent toxicity proﬁle with
a broad range of gemcitabine dosages (350–800 mg/m2).
Gemcitabine administered as single agent biweekly at
dosages ranging from 300 to 675 mg/m2 to dogs with
various solid tumors was well-tolerated, with minimal
toxicosis.3 In another study, when gemcitabine was
administered to dogs with lymphoma at a dosage of
400 mg/m2, treatment was either delayed or interrupted
because of hematologic toxicoses, with no objective
antitumor response.4 Gemcitabine used as single agent
at the weekly dose of 800 mg/m2 for the adjuvant treat-
ment of mammary carcinoma caused grade 1 neutrope-
nia in 4 of 61 treatments, and grade 1–2 gastrointestinal
toxicosis in 2 of 61 treatments.5 Dogs with transitional
cell carcinoma (TCC) of the urinary bladder treated
with weekly gemcitabine at 800 mg/m2 had a favorable
toxicosis proﬁle.6 Gemcitabine administered at 295–450
mg/m2 weekly for 5 weeks to 15 dogs with hepatocellu-
lar carcinoma was associated with minimal toxicosis,
but no survival advantage was demonstrated.7
When considering the published literature, the absence
of relevant hematologic and nonhematologic toxicoses is
of particular interest, suggesting that substantial dose
escalation might be possible in dogs with solid tumors.
Importantly, not only the dose, but also the duration
of exposure of gemcitabine contributes to its cytotoxic-
ity and, consequently, tolerability.8 Prolongation of the
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infusion time in humans beyond 60 minutes increases
toxicoses of gemcitabine.8 An infusion time ranging
from 20 up to 60 minutes are used in dogs.3–7,9
Although gemcitabine has shown some antitumor
activity in various canine solid tumors, its eﬃcacy has
not been fully determined yet. It is possible that treating
dogs with gemcitabine at its maximally tolerated dose
(MTD) might increase chances of eﬃcacy. Indeed, it is
well-known that underdosing of chemotherapeutic
agents leads to reduced eﬀectiveness and, consequently,
to treatment failure. A phase 1 dose-escalation study to
identify the MTD of gemcitabine in tumor-bearing dogs
has not been performed so far. Given the low incidence
of dose-limiting toxicity (DLT) when dogs received
800 mg/m2 of gemcitabine,5,6 it might be hypothesized
that the MTD is likely higher.
The primary aim of this study was to complete a
dose-escalation trial to determine MTD and DLT of
gemcitabine when administered as a single IV dose
infused over 30 minutes. Secondary endpoints were to
assess the safety of repeated dosing and to obtain preli-
minary evidence of antitumor activity in dogs with
advanced solid tumors. Finally, the gemcitabine amount
in urine of treated dogs was monitored to provide safe
handling guidelines.
Materials and Methods
Dogs and Baseline Evaluation
Client-owned dogs were enrolled in the study. Dogs were con-
sidered eligible to receive gemcitabine when they had an inopera-
ble, recurrent, or metastatic solid tumor that had been conﬁrmed
histologically, and for which standard treatment options were not
available or refused by the owners; an expected survival of at least
4 weeks without treatment; not received chemotherapy, immuno-
therapy, or radiotherapy for at least 4 weeks. Additional entry
requirements included an adequate bone marrow, cardiac, renal,
and hepatic function on day 0, as documented by a normal CBC,
renal and hepatic serum chemistry values, thoracic auscultation
and electrocardiogram. Speciﬁcally, dogs were required to have
absolute neutrophil count (ANC) ≥1,500 cells/lL, hematocrit
≥25%, platelet count ≥100, 000/lL, serum creatinine concentration
and alanine transaminase activity ≤2 times the upper limit of nor-
mal, lethargy/fatigue status (VCOG-CTCAE version 1.0) of either
0 or 1.10 Exclusion criteria included second malignancies, concur-
rent serious systemic diseases, body weight <10 kg and age
<1 year.
All owners signed an informed consent indicating their under-
standing of the investigational nature and risks of this study.
Baseline evaluation included physical examination, an electro-
cardiogram, a CBC with diﬀerential and platelet count, serum bio-
chemical analysis, urinalysis, thoracic radiographs, and abdominal
ultrasound. If the disease was not directly measurable by calipers,
a CT scan was performed.
Safety evaluation was performed 7 days after dosing and
included medical history obtained from the owners, physical exami-
nation, CBC with diﬀerential and platelet count, serum biochemical
analysis, and urinalysis with microscopic examination of urine sedi-
ment. The dog’s vital signs and temperature were recorded before
and after each injection of gemcitabine. Body weight was recorded
on day 0 and 7. In case of hematologic toxicosis, blood samples were
collected daily after day 7 until recovery of neutrophil and platelet
counts, whichever was longer.
Toxic eﬀects were graded in accordance with VCOG-CTCAE
guidelines.10 DLT was deﬁned as any grade 3 adverse event, or
grade 4 hematologic toxicosis that developed during a 7-day obser-
vation period. The MTD was deﬁned as the highest dose level that
resulted in a DLT in no more than one of 6 dogs.
Dose Escalation
This study was conducted as a prospective open-label phase 1
dose-cohort (3 + 3) escalation design that investigated the MTD
and DLTs occurring over a 7-day period after a single IV dose of
gemcitabine.11
Handling and administration of gemcitabine, as well as disposal
of related waste, were done according to guidelines on chemother-
apy use in veterinary oncology.12
Each dog received a ﬁrst dose of gemcitabine as a 30 minute IV
infusion. The initial dose was set at 800 mg/m2 on the basis of the
results of previous studies showing good tolerability.5,6 Dose
increases were evaluated in cohorts of 3 dogs. If none of the 3
treated dogs in a given cohort developed DLT after the 7 day
assessment, the dose of gemcitabine for the next cohort was
increased by 50 mg/m2. If one of the dogs developed DLT, an
additional 3 dogs were treated at that dose; if no additional dogs
developed DLT at that dose, the dose escalation was continued. If
≥2 dogs in a cohort developed DLT, no further dose escalations
were performed and the MTD was considered exceeded. If a dog
developed DLT, the dose was decreased by 1 dosage level for the
following treatment.
Once MTD was established, escalation was stopped, and at
least 3 additional dogs were treated with gemcitabine at that dose
to further characterize any associated toxicosis and to characterize
the extent of urinary excretion, leading to a minimum of 6 dogs
treated at MTD. No intradog dose escalation was performed in
this study.
Standard prophylactic anti-emetic treatment was provided (mar-
opitanta 2 mg/kg PO daily for 3 days) to all dogs. General symp-
tom management and supportive care were provided as clinically
indicated.
Response to Therapy
Gemcitabine was administered once weekly, and a minimum of
3 treatment cycles was required for a dog to be considered evalu-
able for antitumor response. Antitumor activity was assessed by
standard criteria based on caliper or CT measurement evaluation,
depending on tumor site.13 Response had to last for at least
28 days.
Dogs whose disease was responding or stable were oﬀered to
continue therapy for at least 6 cycles at the same dose level and
schedule. Clients were allowed to remove their dog from the pro-
tocol in case of disease progression, other signs of compromised
health, or in case of unacceptable toxicosis, at the discretion of the
investigator, owner, or both.
Urine Sampling and Determination of Gemcitabine
Residues
Once having ﬁnished the dose escalation and determined MTD,
urine residues were monitored in 4 dogs treated at this dose.
Urine samples (5 mL) were collected in 30 mL polypropylene
tubes using voided urine at diﬀerent time points. For 1 dog only,
urine was sampled once daily in the morning starting 24 hours
after administration gemcitabine until day 10 postinfusion. For the
following 3 dogs, urine was sampled immediately before gemcita-
bine administration, and then 12 and 24 hours after the end of
infusion. Samples were stored at 20°C until analysis.
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A sensitive, selective, and quantitative method for the analysis
of gemcitabine in urine samples was developed according to a pre-
viously described procedure.14 The samples were analyzed in ultra-
performance liquid chromatography coupled with tandem mass
spectrometry (UPLC/MS-MS) operating in multiple reactions
monitoring (MRM mode) in ESI positive. The UPLC/MS-MS
variables were optimized and calibrated a wide concentration
range (0.01–100 ng/mL). The recovery of gemcitabine was >85%
with CV <3%.
Statistical Analysis
In keeping with Phase 1 trial design, no analyses were per-
formed beyond simple descriptive statistics (eg, mean, median) for
the population under study.
Results
Animals
Between July 2011 and December 2013, 22 dogs with
various solid tumors were entered into this Phase 1 trial
and received gemcitabine at 4 diﬀerent dose levels: 3
dogs were enrolled in the 800 mg/m2 cohort, 3 in the
850 mg/m2 cohort, 13 in the 900 mg/m2 cohort, and 3
in the 950 mg/m2 cohort.
There were 10 mixed-breed dogs, 2 Pitt bull, 2 Ger-
man Shepherd dogs, and 1 each of American Staﬀord-
shire Terrier, Cocker spaniel, Irish Terrier, Schnauzer,
Dalmatian, Labrador retriever, Golden retriever, and
Czechoslovakian wolf. There were 15 spayed females
and 7 males (of which 5 neutered). Median age was
10 years (range, 6–13 years), and median weight was
27.9 kg (range, 14.2–39.1 kg).
Seventeen dogs had TCC involving the urinary tract,
4 dogs had a metastatic mammary carcinoma, and 1
dog had a lung carcinoma. Eighteen (82%) dogs had no
prior treatment before the administration of gemcita-
bine, and had macroscopic tumors at the time of enroll-
ment. The 4 dogs with mammary carcinoma underwent
prior surgery; in all of them, the pathologist described
the presence of neoplastic emboli and metastatic regio-
nal lymph nodes. Furthermore, 1 dog also had pulmo-
nary metastases. These 4 dogs were treated with
gemcitabine in the adjuvant setting.
None of the dogs had received previous chemother-
apy and no comorbidities were identiﬁed.
Determination of MTD and DLT
All dogs were used for toxicity assessment evident
after 1 gemcitabine administration. Table 1 shows the
results of hematologic and nonhematologic toxicoses by
dose level for each dog at that dose.
A total of 131 drug administrations have been given
with doses ranging from 800 to 950 mg/m2 and with a
median of 6 cycles per dog (range, 1–25). No death
caused by treatment-related toxicoses occurred. Overall,
neutropenia was identiﬁed as the dose-limiting toxic
event. Table 2 displays the median nadir of the ANC,
packed cell volume, hemoglobin, and platelets by
cohort. Neutropenia of some degree was recognized in
11 of the 22 dogs tested (50%), and in all 11 dogs the
neutropenia was identiﬁed 1 week after treatment.
Gemcitabine was administered at 800, 850, and
900 mg/m2 for the ﬁrst 3 cohorts. None of the 3 dogs
enrolled in each of these cohorts experienced a DLT.
One of 3 dogs at 850 mg/m2 had grade 1 nonfebrile
neutropenia and anemia, and 1 of these had grade 2
nonfebrile neutropenia and grade 1 anemia. At 900 mg/
m2 2 of 3 dogs experienced grade 1 nonfebrile neutrope-
nia, 1 dog experienced grade 1 anemia, and 1 of these
had grade 1 gastrointestinal toxicity, consisting of loss
of appetite and nausea.
Of the 3 dogs that were enrolled in the subsequent
950 mg/m2 cohort, 2 experienced a DLT consisting of
febrile grade 4 neutropenia. Both dogs were hospital-
ized, received intravenous administration of antibiotics,
and recovered after 1 week with no prolonged neutro-
penia. One of these dogs was withdrawn from the
Table 1. Hematologic and nonhematologic toxicoses by dog and dose level following administration of a single
dose of gemcitabine.
Dose (mg/m2) No. of Dogs No. of Courses
BM Toxicoses, Grade
(no. of dogs) After 1 Course
Gastrointestinal Toxicoses,
Grade (no. of dogs) After 1 Course
800 3 43 0 (3) 0 (2), 1 (1)
850 3 22 0 (1), 1 (1), 2 (1) 0 (1), 2 (2)
900 13 61 0 (7), 1 (5), 2 (1) 0 (10), 1 (3)
950 3 5 2 (1), 4 (2) 0 (1), 2 (2)
Table 2. Hematologic toxicity among the ﬁrst treatment cycle.
Dose (mg/m2) Median ANC/lL (range) Median Hgb (g/dL) (range) Median PCV (range) Median Platelets 9 103/lL (range)
800 3,900 (3,200–5,600) 14.2 (13.1–14.6) 51 (49–52) 265 (230–370)
850 1,600 (1,400–8,200) 10.9 (10.8–11.7) 41 (41–44) 147 (117–228)
900 5,400 (1,002–10,700) 13.1 (10.5–18.5) 43.1 (35–53) 271 (120–577)
950 300 (280–1,001) 12.8 (11.4–13.0) 40 (37–52) 289 (174–345)
Hg, hemoglobin.
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study; and the second was treated with alternative che-
motherapy. The third dog treated at 950 mg/m2 experi-
enced grade 2 hematologic toxicity; he received 2
further cycles of gemcitabine at the same dosage.
Regarding nonhematologic adverse events, 2 dogs expe-
rienced grade 2 gastrointestinal toxicoses consisting of
loss of appetite and vomiting. Other nonhematologic
toxicoses were not observed, as documented by the
serum biochemistry panel (data not shown).
Based on these results, the MTD for the weekly gem-
citabine dosing schedule was determined to be 900 mg/
m2; 10 additional dogs were treated at that dose level to
further evaluate toxic eﬀects and in order to deﬁne the
excretion proﬁle. None of these dogs developed DLT.
Three dogs developed grade 1 nonfebrile neutropenia
and 1 dog grade 2 nonfebrile neutropenia. Two dogs
only experienced grade 1 gastrointestinal toxicoses (loss
of appetite).
On the basis of these results, 900 mg/m2 as a 30 min-
ute IV infusion was determined to be the dosage of
gemcitabine for use in future Phase 2 trials in dogs with
solid tumors.
Cumulative Dosing
Twenty dogs received multiple doses of gemcitabine:
3 dogs were in the 800 mg/m2 cohort and received 8,
10, and 25 doses on a weekly basis; 3 dogs were in the
850 mg/m2 cohort and received 5, 6, and 11 doses; 13
dogs were in the 900 mg/m2 cohort and received 2
(n = 1), 3 (n = 2), 4 (n = 4), 6 (n = 5), and 7 (n = 1)
doses; and 1 dog was in the 950 mg/m2 cohort and
received 3 doses. The intradog dosage of gemcitabine
was kept constant for these 20 dogs. Overall, none of
the dogs receiving multiple treatments on a weekly basis
experienced severe toxicosis from any of their subse-
quent treatments, demonstrated by clinical history and
CBCs performed 1 week after all additional treatments.
Clinical Response and Antitumor Activity
Eighteen dogs were available for clinical response
after 1 dose of gemcitabine. Among them, 13 dogs with
urinary TCC and 1 dog with pulmonary carcinoma
experienced clinical improvement. Three dogs with uri-
nary TCC were stable, whereas 1 dog with urinary TCC
had worsened clinical signs.
Four dogs had microscopic disease at baseline and no
clinical signs; therefore, these dogs were not assessable
for gemcitabine-induced clinical beneﬁt.
Responses could not be ascertained for 3 dogs, which
did not complete 3 cycles of treatment, whereas 19 dogs
(16 dogs with macroscopic tumors and 3 dogs with
microscopic tumors) having received at least 3 cycles of
gemcitabine were available for tumor response.
Among the 16 dogs with measurable tumors, 2
achieved complete remission (CR) (1 dog with pulmo-
nary metastases from a mammary carcinoma, 1 TCC),
11 dogs with TCC achieved partial remission (PR),
and 3 dogs achieved SD (2 TCC and 1 lung carci-
noma), for an overall response rate in the macroscopic
setting of 88.9% (Table 3). Among responding dogs,
median duration of response was 262 days (range,
42–1,784 days).
Three dogs with surgically removed metastatic mam-
mary carcinoma and neoplastic emboli did not progress
during the study period, 65, 209, and 405 days after
enrollment.
All CR (including the 3 dogs with microscopic dis-
ease) were observed at the 900 mg/m2 dose level. PR
were documented at the following dose levels: 800 mg/
m2 (n = 2), 850 mg/m2 (n = 3), and 900 mg/m2 (n = 6).
All responding dogs continued to receive gemcitabine
treatment until completion of six or more planned
courses (n = 6), treatment change (n = 5), or tumor
progression (n = 5).
Gemcitabine Levels in Urine
Gemcitabine levels were determined in 19 urine sam-
ples collected at several time points before and after the
administration of chemotherapy in 4 dogs treated at the
MTD. After 12 hours, the gemcitabine concentration
was 4.1, 1.26, 1.84, and 1.78 ng/mL respectively. For all
dogs, it was impossible to recover any residue after
24 hours after administration of gemcitabine.
Discussion
Previous experience with single-agent gemcitabine
administered at diﬀerent dosing and schedule options to
dogs with tumors other than lymphoma was encourag-
ing; therefore the current Phase 1 clinical trial was con-
ducted to determine MTD and DLT.
Doses and schedule adopted in former clinical trials
included gemcitabine administered at 300–675 mg/m2
every 2 weeks,3 weekly 800 mg/m2,5,6 and weekly 350–
400 mg/m2,7 with a good safety proﬁle, suggesting that
substantial dose escalation might be possible. Indeed, in
the present study, the MTD for gemcitabine administered
Table 3. Responses to gemcitabine in 16 dogs with macroscopic tumors having received at least 3 doses of gemcita-
bine.
Cohort (mg/m2) No. of Dogs Type of Tumor CR PR SD PD
800 3 TCC (3) 0 2 1 0
850 3 TCC (3) 0 3 0 0
900 9 TCC (7), mammary carcinoma (1), lung carcinoma (1) 2 6 1 0
950 1 TCC (1) 0 0 1 0
PD, progressive disease.
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as a 30-minute infusion to chemotherapy-na€ıve dogs with
advanced solid tumors was weekly 900 mg/m2.
Dose escalation on this study was planned in a tra-
ditional manner with a minimum of 3 dogs to be
entered at each dose level. No new dogs were to
receive an escalated dose until all dogs at the current
dose level had been observed for a minimum of 7 days.
At 900 mg/m2, the major toxicities were grade 1–2
short-lived neutropenia and transient nausea and vom-
iting. Gemcitabine was otherwise well-tolerated with
none of the dogs developing grade 3–4 neutropenia or
further adverse eﬀects. Importantly, there were no
deaths with this dosage, and no related life-threatening
complications.
There were two cases of DLT when gemcitabine was
administered at 950 mg/m2, consisting of grade 4 febrile
neutropenia, which was not seen in any other dogs trea-
ted at lower dosages. Both DLTs recovered after hospi-
talization and symptomatic treatment; their neutrophil
counts were within normal limits 14 days after dosing.
Notably, of the 20 dogs that received ≥3 gemcitabine
treatments, none had any clinically relevant decrease in
neutrophils, hematocrit, hemoglobin or platelet count
over time, suggesting that neutropenia was not cumula-
tive, and that gemcitabine might not irreversibly dam-
age hematopoietic cells.
In contrast with the toxicoses observed in our study,
dogs with lymphoma treated with gemcitabine at
400 mg/m2 experienced severe hematologic toxicoses,
which is much lower than the MTD found here.4 This
discrepancy might be attributable to the systemic nature
of lymphoma. Indeed, approximately 20% of the dogs
in that study had bone marrow involvement, possibly
explaining the occurrence of grade 3 (9%) or 4 (5%)
neutropenia.
Gemcitabine is an eﬀective agent in the treatment of
many human tumors. Although eﬃcacy was not a pri-
mary endpoint of this trial, we found preliminary evi-
dence of antitumor activity after a single-dose
administration as well as evidence of a dose response.
When treated at gemcitabine MTD on a weekly basis, all
7 dogs with TCC responded to treatment (1 CR and 6
PR), and none progressed. Although quite unexpected,
these results should not be surprising, as there is substan-
tial evidence that dose-intensity is an important determi-
nant of outcome in the treatment of solid tumors with
cytotoxic chemotherapy.15 It is possible that administer-
ing gemcitabine at MTD might have maximized activity,
leading to a better response rate compared with the same
drug administer at a lower dose.6
Furthermore, all 4 dogs with metastatic mammary
carcinoma did not progress and among them, 1 dog
with lung metastases experienced CR, as demonstrated
by follow-up CT. Notably, because response was evalu-
ated after only 3 doses of gemcitabine, responses might
be further improved by additional cycles.
The presence of chemotherapy residues in dogs’
urines might represent an exposure hazard for owners
and other animals sharing the same environment.12
Previous studies have attempted to measure urine
residues of vincristine, vinblastine, cyclophosphamide,
doxorubicin, and carboplatin.16,17 Urine residues of
gemcitabine were detectable in treated dogs immediately
after the administration. However, after 24 hours, drug
residues in urine were below the limits of detection with
trace concentrations only measurable in single samples,
indicating that after 24 hours the urine might be consid-
ered free of exposure hazard. Even though gemcitabine
metabolites were not measured, these are thought to be
inactive in humans,18 thereby not being relevant for
environmental contamination.
Limitations of the current study are the small pop-
ulation and the varied dose-intensity cohorts. Despite
the good toxicity proﬁle and the encouraging
observed response rates in dogs with TCC, we
acknowledge that larger more appropriately powered
disease-speciﬁc studies are necessary to more carefully
characterize the eﬃcacy of gemcitabine administered
at its MTD. Also, whether a higher cumulative dose
translates into higher response rates will need to be
further evaluated.
In conclusion, therapeutic doses associated with eﬃ-
cacy of gemcitabine monotherapy were achieved. The
safety and preliminary eﬃcacy results of this study sug-
gest that the weekly 900 mg/m2 schedule is suitable for
further exploration in Phase 2 clinical trials focused on
dogs with TCC.
Footnote
a Cerenia, Zoetis, Rome, Italy
Acknowledgment
Conﬂict of Interest Declaration: Authors disclose no
conﬂict of interest.
Oﬀ-label Antimicrobial Declaration: Authors declare
no oﬀ-label use of antimicrobials.
References
1. Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination
of 20,20-diﬂuorodeoxycytidine 50-triphosphate: A mechanism of
self-potentiation. Cancer Res 1992;52:533–539.
2. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: Metabo-
lism, mechanisms of action and self-potentiation. Semin Oncol
1995;22:3–10.
3. Kosarek CE, Kisseberth WC, Gallant SL, et al. Clinical
evaluation of gemcitabine in dogs with spontaneously occurring
malignancies. J Vet Intern Med 2005;19:81–86.
4. Turner AI, Hahn KA, Rusk A, et al. Single agent gemcita-
bine chemotherapy in dogs with spontaneously occurring lym-
phoma. J Vet Intern Med 2006;20:1384–1388.
5. Marconato L, Lorenzo RM, Abramo F, et al. Adjuvant
gemcitabine after surgical removal of aggressive malignant mam-
mary tumours in dogs. Vet Comp Oncol 2008;6:90–101.
6. Marconato L, Zini E, Lindner D, et al. Toxic eﬀects and
antitumor response of gemcitabine in combination with piroxicam
treatment in dogs with transitional cell carcinoma of the urinary
bladder. J Am Vet Med Assoc 2011;238:1004–1010.
624 Marconato et al
7. Elpiner AK, Brodsky EM, Hazzah TN, et al. Single-agent
gemcitabine chemotherapy in dogs with hepatocellular carcinomas.
Vet Comp Oncol 2011;9:260–268.
8. Abbruzzese JL. Phase I studies with the novel nucleoside
analog gemcitabine. Semin Oncol 1996;23:25–31.
9. Freise KJ, Martin-Jimenez T. Pharmacokinetics of gemcita-
bine and its primary metabolite in dogs after intravenous infusion.
J Vet Pharmacol Ther 2006;29:147–152.
10. Veterinary cooperative oncology group. Veterinary coopera-
tive oncology group- common terminology criteria for adverse
events (VCOG-CTCAE) following chemotherapy or biological
antineoplastic therapy in dogs and cats v1.0. Vet Comp. Oncol
2004;2:194–213.
11. Vail DM. Cancer clinical trials: Development and imple-
mentation. Vet Clin North Am Small Anim Pract 2007;37:1033–
1057.
12. Preventing occupational and environmental exposure to
cytotoxic drugs in veterinary medicine, 2nd ed. European College
of Veterinary Internal Medicine of Companion Animals; 2007.
Available at: http://www.ecvim-ca.org. Accessed August 15th,
2014.
13. Nguyen SM, Thamm DH, Vail DM, London CA.
Response evaluation criteria for solid tumours in dogs (v1.0): A
Veterinary Cooperative Oncology Group (VCOG) consensus docu-
ment. Vet Comp Oncol 2013; Accessed August 15, 2014. doi:
10.1111/vco.12032. [Epub ahead of print]
14. Mendu DR1, Soldin SJ. Simultaneous determination of lev-
etiracetam and its acid metabolite (ucb L057) in serum/plasma by
liquid chromatography tandem mass spectrometry. Clin Biochem
2010;43:485–489.
15. Dodwell DJ, Gurney H, Thatcher N. Dose intensity in can-
cer chemotherapy. Br J Cancer 1990;61:789–794.
16. Janssens T, Brouwers EE, de Vos JP, et al. Inductively cou-
pled plasma mass-spectrometric determination of platinum in
excretion products of client-owned pet dogs. Vet Comp Oncol
doi:10.1111/vco.12025.
17. Knobloch A, Mohring SA, Eberle N, et al. Cytotoxic drug
residues in urine of dogs receiving anticancer chemotherapy. J Vet
Intern Med 2010;24:384–390.
18. Lokiec F, Lansiaux A. Gemcitabine: De la preclinique a la
clinique en passant par la pharmacocinetique. Bull Cancer
2007;94:S85–89.
Dose-escalation of Gemcitabine in Dogs 625
